352303-79-8

Basic information

• Product Name: Carbamic acid, [(1R)-2-[5-bromo-3-[(2,6-difluorophenyl)methyl]-3,6-dihydro-4-methyl-2, 6-dioxo-1(2H)-pyrimidinyl]-1-cyclohexylethyl]-, 1,1-dimethylethyl ester
• CAS NO: 352303-79-8
• Molecular Formula: C25H32BrF2N3O4
• Molecular Weight: 556.448
• Mol File: 352303-79-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(1R)-2-[5-bromo-3-[(2,6-difluorophenyl)methyl]-3,6-dihydro-4-methyl-2, 6-dioxo-1(2H)-pyrimidinyl]-1-cyclohexylethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-2-[5-bromo-3-[(2,6-difluorophenyl)methyl]-3,6-dihydro-4-methyl-2, 6-dioxo-1(2H)-pyrimidinyl]-1-cyclohexylethyl]-, 1,1-dimethylethyl ester(352303-79-8)
• EPA Substance Registry System: Carbamic acid, [(1R)-2-[5-bromo-3-[(2,6-difluorophenyl)methyl]-3,6-dihydro-4-methyl-2, 6-dioxo-1(2H)-pyrimidinyl]-1-cyclohexylethyl]-, 1,1-dimethylethyl ester(352303-79-8)

Safety Data

• Hazardous Substances Data: 352303-79-8(Hazardous Substances Data)

Upstream product

• 1312023-04-3 tert-butyl-1-cyclohexyl-2-hydroxyethylcarbamate 
• 352303-66-3 5-bromo-1-(2,6-difluoro-benzyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 70491-05-3 (2R)-[(tert-butoxycarbonyl)-amino](cyclohexyl)ethanoic acid 
• 188348-00-7 (R)-1-(cyclohexyl-2-hydroxyethyl)carbamic acid tert-butyl ester 

Downstream Products

• 352303-81-2 (R)-3-(N-tert-butoxycarbonyl-2-amino-2-cyclohexylethyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyluracil 
• 352290-67-6 3-[2(R)-amino-2-cyclohexylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2,6-difluorobenzyl]-6-methyl-pyrimidine-2,4-(1H,3H)-dione 

Relevant articles and documents

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

3-(2-Aminoalkyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl) -6-methyluracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor

Uracils possessing N-3 side chains derived from various amino alcohols were designed and synthesized as potent human gonadotropin releasing hormone receptor antagonists. The compounds herein presented displayed superior metabolic stability than their pred